Anthony Jesús Pastrana Villares

Anthony Jesús Pastrana Villares

Auto-generated profile, based on publicly available information

Anthony Jesús Pastrana Villares

Investigador Independiente

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in SAGA: Revista Científica Multidisciplinar
Verified
Journal Article
Open access
PDF file
JEJorge Angel Velasco Espinal
Jorge Angel Velasco Espinal
ATAlexander Travisi
Alexander Travisi
PLPablo Daniel Heráldez León
Pablo Daniel Heráldez León
SSSebastian Guardiola Segovia
Sebastian Guardiola Segovia
LVLuis Enrique Jimenez Vazquez
Luis Enrique Jimenez Vazquez
AVAnthony Jesús Pastrana Villares
Anthony Jesús Pastrana Villares
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, driven by biological, behavioral, and social determinants. This study evaluated the impact of integrating biomarker-based early detection with culturally tailored community interventions on cardiovascular risk across diverse populations. A stratified observational design included adults aged 18 to 75 years from different socioeconomic and educational backgrounds, with balanced representation of men and women. Participants underwent biomarker testing for blood pressure, glucose, and lipids, and completed lifestyle surveys on diet, physical activity, and smoking status. Interventions included dietary counseling, peer-led support groups, and mobile health tools. Outcomes were assessed by changes in clinical indicators and prevalence of multiple risk factors. Results showed significant reductions in systolic blood pressure (mean −10 mmHg), fasting glucose (−12 mg/dL), and LDL cholesterol (−15%). Lifestyle changes included increased adherence to physical activity guidelines (42% to 61%), improved healthy diet adherence (36% to 54%), and a reduction in smoking prevalence (non-smokers from 79% to 86%). Subgroup analyses demonstrated benefits across genders, age groups, socioeconomic strata, and educational levels, with the greatest reductions observed in high baseline risk individuals (≥2 risk factors: 52% to 33%). The study concludes that combining early detection with community-based strategies provides measurable improvements in both clinical and behavioral determinants of CVD risk. These findings support multilevel prevention frameworks and suggest that integrated approaches can reduce disparities and contribute to lowering the global burden of cardiovascular disease.

1 July 2025 in SAGA: Revista Científica Multidisciplinar
Verified
Journal Article
Open access
PDF file
ESErick Adolfo Meza Soto
Erick Adolfo Meza Soto
AVAnthony Jesús Pastrana Villares
Anthony Jesús Pastrana Villares
EGErick Tirado Gárate
Erick Tirado Gárate
BHBerenice Lira Hernández
Berenice Lira Hernández
BTBryan Steeven Lapo Torres
Bryan Steeven Lapo Torres
RORafael Rodríguez Ornelas
Rafael Rodríguez Ornelas
Precision chemotherapy represents a paradigm shift in oncology, tailoring cytotoxic regimens to molecular tumor profiles to improve efficacy and reduce toxicity. A multicenter observational study was conducted in Mexico and Ecuador with patients diagnosed with breast, colorectal, ovarian, and cervical cancers. Clinical and demographic data were collected, and molecular profiling was performed using tissue-based next-generation sequencing (NGS) and plasma-derived circulating tumor DNA (ctDNA). Outcomes included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), toxicity, and patient-reported quality of life (QoL). High concordance above 80% was observed between NGS and ctDNA for key biomarkers, with BRCA1/2 and MMR/MSI alterations associated with superior ORR, PFS, and OS, whereas KRAS mutations correlated with poorer outcomes. Biomarker-guided chemotherapy significantly reduced grade ≥3 adverse events compared with conventional regimens and improved QoL scores by 8–10 points across functional domains (EORTC QLQ-C30). These findings confirm that precision chemotherapy enhances efficacy, tolerability, and patient-centered outcomes, while the binational experience in Mexico and Ecuador highlights both feasibility and the urgent need for equitable access to molecular diagnostics in Latin America. Precision chemotherapy should be prioritized as a central component of global cancer control strategies.

30 June 2026 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
CLCristobal Washigton Franco Lucas
Cristobal Washigton Franco Lucas
GVGerardo Amaya Villagran
Gerardo Amaya Villagran
JAJhon Alexander Ponce Alencastro
Jhon Alexander Ponce Alencastro
AVAnthony Jesús Pastrana Villares
Anthony Jesús Pastrana Villares
AOAndres Sebastián Freire Ortega
Andres Sebastián Freire Ortega
AOAshley Denisse Ayala Ochoa
Ashley Denisse Ayala Ochoa
Chronic kidney disease (CKD) without diabetes mellitus has become an increasingly recognized clinical entity whose progression cannot be explained exclusively by traditional hemodynamic mechanisms. Growing evidence indicates that endocrine dysregulation, metabolic remodeling, mitochondrial dysfunction, chronic inflammation, oxidative stress, and altered communication between the kidney and other organ systems play fundamental roles throughout disease development and progression. The present review critically analyzes current scientific evidence regarding the endocrine and metabolic mechanisms involved in non-diabetic CKD, integrating findings from nephrology, endocrinology, and internal medicine while incorporating information relevant to Latin American populations. A narrative review based on the Scientific Method was conducted using high-quality publications retrieved from internationally recognized databases and clinical practice guidelines. The available evidence demonstrates that persistent activation of the renin–angiotensin–aldosterone system, disruption of the fibroblast growth factor 23–Klotho axis, impaired vitamin D metabolism, insulin resistance, obesity-related endocrine alterations, mitochondrial dysfunction, and gut–kidney interactions contribute substantially to renal fibrosis, progressive loss of kidney function, and cardiovascular complications. Contemporary therapeutic approaches, particularly sodium–glucose cotransporter-2 inhibitors, have significantly modified disease management by providing nephroprotective effects beyond glycemic control. Emerging biomarkers and precision medicine strategies also show considerable potential for improving early diagnosis, individualized risk assessment, and targeted therapeutic interventions. Nevertheless, additional multicenter studies, particularly involving underrepresented regions such as Latin America, remain necessary to strengthen the current evidence base. Overall, non-diabetic CKD should be regarded as a complex multisystem disorder requiring an integrated clinical approach that combines endocrine, metabolic, cardiovascular, and nephrological perspectives to optimize patient outcomes.

1 July 2024 in Ibero-American Journal of Health Science Research
Verified
Journal Article
Open access
FNFernanda De Las Mercedes López Naveda
Fernanda De Las Mercedes López Naveda
AAAkemi Rocío Plaza Alcívar
Akemi Rocío Plaza Alcívar
ICIrina Talia Guzmán Chávez
Irina Talia Guzmán Chávez
ACAna Karina Guamán Cevallos
Ana Karina Guamán Cevallos
AVAnthony Jesús Pastrana Villares
Anthony Jesús Pastrana Villares
ABAna Gabriela Castro Bojorque
Ana Gabriela Castro Bojorque
Background: Atopic dermatitis (AD)_ chronic inflammatory skin disorder, has affected the global population. Specifically, it is seen as more common in children about 10-20% prevalence in children’s and 2% among adults. Traditional treatments are insufficient for moderate to severe cases and necessitate new therapeutic options. Janus kinase (JAK) inhibitors is promising class of drugs due to their ability to modulate key inflammatory pathways involved in AD. Methodology: Systematic review was conducted using Cochrane Library database, PubMed, and Embase. Keywords and MeSH terms identified studies focusing on adult patients with moderate to severe AD. Inclusion criteria encompassed studies evaluating efficacy and safety of JAK inhibitors. Data extraction was performed using standardized forms, Cochrane Risk of Bias Tool conducted. Most of the articles are selected which are published in 2024 to keep our research up-to-date. Results: We have analyzed data from several studies evaluating the efficacy and safety of JAK inhibitors, most commonly abrocitinib, upadacitinib, and baricitinib. They have shown efficacy in reducing eczema symptoms with EASI-75 response rates of up to 80% for upadacitinib and 71% for abrocitinib. Higher doses of JAK inhibitors raised safety concerns like heart diseases, infections, and acne, but the standard recommended dose stood beneficial in reducing eczema. Conclusion: JAK inhibitors are advancements in the treatment of moderate to severe atopic dermatitis. They offer substantial symptom relief and improved quality of life.

27 December 2025 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
MGMartin Gomez-Lujan
Martin Gomez-Lujan
GVGerardo Amaya Villagran
Gerardo Amaya Villagran
BBBrenda Mishell Ruiz Borja
Brenda Mishell Ruiz Borja
AVAnthony Jesús Pastrana Villares
Anthony Jesús Pastrana Villares
VAVera Sanchez Brandon Abel
Vera Sanchez Brandon Abel
CLCristobal Washigton Franco Lucas
Cristobal Washigton Franco Lucas
Cardiometabolic diseases currently represent one of the leading causes of morbidity and mortality worldwide. The growing coexistence of obesity, insulin resistance, type 2 diabetes mellitus, hypertension, dyslipidemia, chronic kidney disease, and cardiovascular disease has contributed to the development of the cardiometabolic continuum concept, which describes the progressive interaction between metabolic and cardiovascular dysfunction. The objective of this review was to analyze the current scientific evidence regarding the integration of cardiovascular and endocrine risk factors within contemporary clinical practice, emphasizing pathophysiological mechanisms, epidemiological impact, preventive strategies, and therapeutic approaches associated with cardiometabolic disease. A narrative and analytical literature review was conducted using scientific databases including PubMed, Scopus, ScienceDirect, and major international medical journals. Priority was given to clinical guidelines, randomized clinical trials, systematic reviews, and epidemiological studies published in recent years. The analysis focused on the relationship between obesity, inflammation, endothelial dysfunction, insulin resistance, atherosclerosis, cardiovascular disease, and chronic kidney disease, with particular attention to Latin American populations from Mexico, Colombia, and Ecuador. The reviewed evidence demonstrated that cardiometabolic diseases evolve through interconnected inflammatory, metabolic, vascular, and renal mechanisms rather than isolated pathological processes. Obesity and insulin resistance were identified as major contributors to systemic inflammation, endothelial injury, oxidative stress, and accelerated cardiovascular deterioration. Major clinical trials evaluating sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists showed significant reductions in cardiovascular events, heart failure hospitalization, renal disease progression, and cardiometabolic complications.

30 June 2026 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
JEJorge Angel Velasco Espinal
Jorge Angel Velasco Espinal
ANAlexa Fernanda Uriostegui Navarro
Alexa Fernanda Uriostegui Navarro
AVAnthony Jesús Pastrana Villares
Anthony Jesús Pastrana Villares
DGDominique Isaac Nuñez Gonzalez
Dominique Isaac Nuñez Gonzalez
MRMarlies Solís Rodríguez
Marlies Solís Rodríguez
DGDaniel Alberto Madrid González
Daniel Alberto Madrid González
Long-duration human spaceflight exposes the organism to an environment characterized by microgravity, altered mechanical loading, cephalad fluid redistribution, radiation exposure, confinement, and other factors capable of modifying physiological homeostasis. This review aimed to analyze and integrate current evidence concerning cardiovascular, metabolic, and systemic adaptations associated with prolonged space missions, emphasizing their mechanisms, recovery patterns, and relevance to future human exploration. A structured narrative review based on the scientific method was conducted using international peer-reviewed literature, with priority given to studies indexed in PubMed/MEDLINE and Scopus and to evidence derived from human spaceflight, longitudinal observations, clinically relevant reports, and complementary physiological investigations. The reviewed evidence identified cardiovascular and hemodynamic responses as the predominant research domain, particularly fluid redistribution, plasma-volume regulation, cardiac and vascular remodeling, altered venous circulation, blood-pressure regulation, and postflight orthostatic intolerance. Metabolic and musculoskeletal findings included mechanical unloading, changes in bone remodeling and mineral regulation, physical deconditioning, and alterations that may persist after return to gravity. Renal, immune, molecular, neurovascular, and neuro-ocular responses further demonstrated the multisystem nature of human adaptation to prolonged spaceflight. Recovery was heterogeneous among physiological domains: fluid-volume regulation tended to readjust comparatively rapidly, whereas cardiovascular function, cardiac structure, and immune or molecular responses showed variable trajectories, and some skeletal and neuro-ocular alterations demonstrated slower or incomplete recovery. These findings indicate that long-duration spaceflight should be understood as an integrated physiological challenge requiring longitudinal and individualized monitoring. Future lunar, Martian, and deep-space missions will require combined cardiovascular, metabolic, musculoskeletal, and systemic countermeasures, together with autonomous medical assessment and broader international collaboration to preserve physiological reserve and operational capacity during sustained human exploration beyond Earth.